Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp. It is able to retain activity against many echinocandin-resistant strains of Candida due to differential avidity for the target site compared to echinocandins. In vivo animal models have demonstrated efficacy in murine models of invasive candidiasis, aspergillosis, and pneumocystis. Due to high bioavailability, it can be administered both orally and intravenously. A favorable drug interaction and tolerability profile is observed with this compound. This review summarizes existing data that have either been published or presented at international symposia.
National trends in incidence, prevalence and disability-adjusted life years of invasive aspergillosis in Iran: a systematic review and meta-analysis (Tavakoli et al., 2019)
This review provides an overview of the epidemiology, prevalence, incidence, clinical manifestations, underlying diseases, survivals, treatments, outcomes, and societal impact through disability-adjusted life years (DALYs) of IA in Iran. It is the first paper published with analyses DALY and other related statistics for invasive aspergillosis.
Amyloidosis secondary to chronic pulmonary aspergillosis: Case report and a systematic review of literature (Patel et al., 2019)
This case report highlights an uncommon complication (secondary amyloidosis) of CPA. The index case presented primarily with features of the nephrotic syndrome that masked the clinical features of CPA.